Regulation of RIG-I signaling and viral immune evasion by ufmylation

通过 ufmylation 调节 RIG-I 信号传导和病毒免疫逃避

基本信息

  • 批准号:
    10620805
  • 负责人:
  • 金额:
    $ 45.67万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-06-01 至 2026-05-31
  • 项目状态:
    未结题

项目摘要

ABSTRACT Type I and III interferons (IFN) restrict RNA virus infection. Infected cells produce IFN through signaling activated by pattern recognition receptors such as RIG-I. Both RIG-I and downstream signaling must be highly coordinated for efficient antiviral responses. As such, these processes are regulated by several post-translational modifications (PTMs). These PTMs are essential for both the activation and eventual termination of RIG-I- signaling. While RIG-I-signaling is coordinated by ubiquitination and phosphorylation, the mechanisms by which other PTMs, such as ubiquitin-like modifiers, may regulate RIG-I-signaling are largely unknown. Our preliminary data reveal that the ubiquitin-like modifier called ufmylation regulates multiple proteins involved in RIG-I signaling for optimal IFN induction in response to viral infection. Further, our data suggest that ufmylation is utilized by viruses to evade the host intracellular innate immune response. Therefore, the goal of this proposal is to determine how ufmylation regulates the intracellular innate immune response to virus infection and viral evasion. Based on our preliminary data, the central hypothesis is that ufmylation modulates the function of host and viral proteins to regulate antiviral innate immunity and viral evasion. Guided by our preliminary data, this hypothesis will be tested by pursuing the following three specific aims: 1) Define how UFL1, the ufmylation E3 ligase, promotes the activation of RIG-I; 2) Understand the molecular mechanism by which ufmylation of a key protein in the RIG-I signaling pathway downregulates its function and signaling; 3) Determine how dengue virus co-opts the ufmylation conjugation system for immune evasion. In Aim 1, the molecular mechanisms by which UFL1 induces the activation of RIG-I in response to RNA virus sensing will be defined. In Aim 2, the mechanism and dynamics of how ufmylation regulates the function of a signaling protein in RIG-I pathway will be determined. In Aim 3, the function by which ufmylation of a DENV protein promotes DENV immune evasion, both in human cell lines and in primary cells, will be determined. Taken together, the work proposed in this application will be significant and innovative because it will attribute a novel immune regulatory function to ufmylation, contribute to our understanding of its basic functions, and uncover a novel control (ufmylation) of antiviral innate immunity. Additionally, this work will provide understanding of a host-directed process that is utilized by viruses for immune evasion to facilitate viral replication. Overall, this work will define a new PTM that coordinates the RIG-I signaling pathway, which will improve our knowledge of both antiviral immunity and regulation of innate immune pathways that will lead to increased understanding of the mechanistic causes of dysregulated IFN that can ultimately result in autoimmune disease. It will also define a new mechanism of immune evasion by flaviviruses that will have implications for therapeutic and vaccine strategies to limit their infection.
摘要 I型和III型干扰素(IFN)限制RNA病毒感染。感染细胞通过激活信号传导产生IFN 通过模式识别受体如RIG-I。RIG-I和下游信号必须高度协调 有效的抗病毒反应。因此,这些过程受到几种翻译后调节。 修改(PTM)。这些PTM对于RIG-I的激活和最终终止都是必不可少的。 信号虽然RIG-I信号转导是通过泛素化和磷酸化来协调的,但RIG-I信号转导的机制是不确定的。 其它可能调节RIG-I信号传导的PTM,如泛素样修饰剂,在很大程度上是未知的。我们的初步 数据显示,称为ufmylation的泛素样修饰物调节参与RIG-I信号传导的多种蛋白质 用于响应病毒感染的最佳IFN诱导。此外,我们的数据表明, 病毒逃避宿主细胞内先天免疫反应。因此,本提案的目标是 确定ufmylation如何调节细胞内对病毒感染和病毒逃逸的先天免疫应答。 基于我们的初步数据,中心假设是,ufmylation调节宿主和病毒的功能, 调节抗病毒先天免疫和病毒逃避的蛋白质。根据我们的初步数据,这个假设 将通过追求以下三个具体目标进行测试:1)定义UFL 1,即磺酰化E3连接酶, 促进RIG-I的活化; 2)理解关键蛋白的磺酰化的分子机制, 在RIG-I信号通路中下调其功能和信号传导; 3)确定登革病毒如何选择 用于免疫逃避的磺酰化缀合系统。在目标1中,UFL 1 诱导RIG-I响应RNA病毒传感的活化。在目标2中,机制和 将确定在RIG-I途径中,磺酰基化如何调节信号蛋白功能的动力学。在 目的3,在人细胞中,DENV蛋白的ufmylation促进DENV免疫逃避的功能, 在原代细胞中,将被确定。综上所述,本申请中提出的工作将 因为它将赋予ufmylation新免疫调节功能,有助于 我们对其基本功能的理解,并揭示了一种新的控制(ufmylation)的抗病毒先天免疫。 此外,这项工作将提供对病毒用于免疫的宿主导向过程的理解。 逃避以促进病毒复制。总之,这项工作将定义一个新的PTM,协调RIG-I信令 这将提高我们对抗病毒免疫和先天免疫途径调节的认识 这将导致增加对IFN失调的机制原因的理解, 自身免疫性疾病它还将定义黄病毒免疫逃避的新机制, 对限制其感染的治疗和疫苗策略的影响。

项目成果

期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Signaling from the RNA sensor RIG-I is regulated by ufmylation.
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Stacy Michelle Horner其他文献

Stacy Michelle Horner的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Stacy Michelle Horner', 18)}}的其他基金

Regulation of RIG-I signaling and viral immune evasion by ufmylation
通过 ufmylation 调节 RIG-I 信号传导和病毒免疫逃避
  • 批准号:
    10414114
  • 财政年份:
    2021
  • 资助金额:
    $ 45.67万
  • 项目类别:
Regulation of RIG-I signaling and viral immune evasion by ufmylation
通过 ufmylation 调节 RIG-I 信号传导和病毒免疫逃避
  • 批准号:
    10295558
  • 财政年份:
    2021
  • 资助金额:
    $ 45.67万
  • 项目类别:
Defining the role of the RNA modification N6-methyladenosine in the hepatitis C virus lifecycle
定义 RNA 修饰 N6-甲基腺苷在丙型肝炎病毒生命周期中的作用
  • 批准号:
    9157887
  • 财政年份:
    2016
  • 资助金额:
    $ 45.67万
  • 项目类别:
Defining novel Riplet-activated antiviral innate immune signaling pathways
定义新型 Riplet 激活的抗病毒先天免疫信号通路
  • 批准号:
    9310220
  • 财政年份:
    2016
  • 资助金额:
    $ 45.67万
  • 项目类别:
Defining the role of the RNA modification N6-methyladenosine during Flaviviridae virus infection
定义 RNA 修饰 N6-甲基腺苷在黄病毒科病毒感染过程中的作用
  • 批准号:
    10444757
  • 财政年份:
    2016
  • 资助金额:
    $ 45.67万
  • 项目类别:
Defining the role of the RNA modification N6-methyladenosine during Flaviviridae virus infection
定义 RNA 修饰 N6-甲基腺苷在黄病毒科病毒感染过程中的作用
  • 批准号:
    10557139
  • 财政年份:
    2016
  • 资助金额:
    $ 45.67万
  • 项目类别:
Defining the role of the RNA modification N6-methyladenosine in the hepatitis C virus lifecycle
定义 RNA 修饰 N6-甲基腺苷在丙型肝炎病毒生命周期中的作用
  • 批准号:
    9283320
  • 财政年份:
    2016
  • 资助金额:
    $ 45.67万
  • 项目类别:
Defining novel Riplet-activated antiviral innate immune signaling pathways
定义新型 Riplet 激活的抗病毒先天免疫信号通路
  • 批准号:
    9090371
  • 财政年份:
    2016
  • 资助金额:
    $ 45.67万
  • 项目类别:
Zika virus infection of neural stem cells to model pathogen-induced microcephaly
寨卡病毒感染神经干细胞来模拟病原体诱导的小头畸形
  • 批准号:
    9266693
  • 财政年份:
    2016
  • 资助金额:
    $ 45.67万
  • 项目类别:
Innate immune regulation during hepatitis C virus infection
丙型肝炎病毒感染期间的先天免疫调节
  • 批准号:
    8352240
  • 财政年份:
    2013
  • 资助金额:
    $ 45.67万
  • 项目类别:

相似海外基金

Dose Flexible Combination 3D-Printed Delivery Systems for Antiviral Therapy in Children
用于儿童抗病毒治疗的剂量灵活组合 3D 打印输送系统
  • 批准号:
    10682185
  • 财政年份:
    2023
  • 资助金额:
    $ 45.67万
  • 项目类别:
COVID-19 Immunologic Antiviral therapy with Omalizumab (CIAO trial) - An Adaptive Phase II Randomized-Controlled Clinical Trial
使用奥马珠单抗进行 COVID-19 免疫抗病毒治疗(CIAO 试验)——适应性 II 期随机对照临床试验
  • 批准号:
    475843
  • 财政年份:
    2022
  • 资助金额:
    $ 45.67万
  • 项目类别:
    Studentship Programs
COVID-19 Immunologic Antiviral therapy with Omalizumab (CIAO trial) - An Adaptive Phase II Randomized-Controlled Clinical Trial
使用奥马珠单抗进行 COVID-19 免疫抗病毒治疗(CIAO 试验)——适应性 II 期随机对照临床试验
  • 批准号:
    474485
  • 财政年份:
    2022
  • 资助金额:
    $ 45.67万
  • 项目类别:
    Studentship Programs
Discovery of Bunyaviral Endonuclease Inhibitors for Antiviral Therapy
用于抗病毒治疗的布尼亚病毒核酸内切酶抑制剂的发现
  • 批准号:
    10683329
  • 财政年份:
    2022
  • 资助金额:
    $ 45.67万
  • 项目类别:
Discovery of Bunyaviral Endonuclease Inhibitors for Antiviral Therapy
用于抗病毒治疗的布尼亚病毒核酸内切酶抑制剂的发现
  • 批准号:
    10481430
  • 财政年份:
    2022
  • 资助金额:
    $ 45.67万
  • 项目类别:
An interdisciplinary approach towards antiviral therapy discovery
抗病毒疗法发现的跨学科方法
  • 批准号:
    nhmrc : 1196520
  • 财政年份:
    2021
  • 资助金额:
    $ 45.67万
  • 项目类别:
    Investigator Grants
Applying an 'omics' approach to predict hepatic decompensation events and hepatocellular carcinoma in veterans after HCV cure with direct acting antiviral therapy
应用“组学”方法预测退伍军人在使用直接作用抗病毒疗法治愈 HCV 后的肝失代偿事件和肝细胞癌
  • 批准号:
    10260234
  • 财政年份:
    2021
  • 资助金额:
    $ 45.67万
  • 项目类别:
Applying an 'omics' approach to predict hepatic decompensation events and hepatocellular carcinoma in veterans after HCV cure with direct acting antiviral therapy
应用“组学”方法预测退伍军人在使用直接作用抗病毒疗法治愈 HCV 后的肝失代偿事件和肝细胞癌
  • 批准号:
    10548114
  • 财政年份:
    2021
  • 资助金额:
    $ 45.67万
  • 项目类别:
Disparities in the Diffusion of Direct-Acting Antiviral Therapy for Hepatitis C among Baby Boomers: A Mixed-Methods Study
婴儿潮一代丙型肝炎直接作用抗病毒疗法传播的差异:一项混合方法研究
  • 批准号:
    10400318
  • 财政年份:
    2020
  • 资助金额:
    $ 45.67万
  • 项目类别:
COVID-19 Immunologic Antiviral therapy with Omalizumab (CIAO trial)
使用奥马珠单抗进行 COVID-19 免疫抗病毒治疗(CIAO 试验)
  • 批准号:
    449805
  • 财政年份:
    2020
  • 资助金额:
    $ 45.67万
  • 项目类别:
    Studentship Programs
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了